To evaluate the therapeutic potential of DCI in AD, we utilized the triple-transgenic (3×Tg-AD) mouse model, which harbors three human familial AD mutations (APP Swedish, MAPT P301L, and PSEN1 M146V) and exhibits progressive Aβ and tau pathology. The gene discussed is MAPT; the disease is Alzheimer disease.